Your browser doesn't support javascript.
loading
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Endocrinology and Metabolism ; : 53-62, 2019.
Article in English | WPRIM | ID: wpr-739219
ABSTRACT
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Acromegaly / Somatostatin / Octreotide / Insurance Coverage / Consensus / Expert Testimony / Insurance, Health Type of study: Practice guideline / Qualitative research Language: English Journal: Endocrinology and Metabolism Year: 2019 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Acromegaly / Somatostatin / Octreotide / Insurance Coverage / Consensus / Expert Testimony / Insurance, Health Type of study: Practice guideline / Qualitative research Language: English Journal: Endocrinology and Metabolism Year: 2019 Type: Article